InterviewGTGioneering Genomics for Health and Wellness
⚕️FY23 revenue up 28% YoY to $8.7 million (AUD)geneType Multi-Risk test now implemented in 64 clinicsPeer-reviewed publication confirms geneType risk test outperforms traditional risk assessments for breast cancer by up to 9xTargeting 10k general practitioners across AustraliaMaterial progress for commercial rollout in US with Alva10 & large payer engagementNew US business manager gaining traction with concierge medicine groups & independent doctor networks.⚕️
⚕️Now everything will be fine!⚕️
Add to My Watchlist
What is My Watchlist?